Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's presentation is scheduled for Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT).
The company will engage in in-person meetings with the investment community during the conference. Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La presentazione dell'azienda è programmata per martedì 4 marzo alle 11:50 EST (8:50 PST / 16:50 GMT).
L'azienda parteciperà a incontri di persona con la comunità degli investitori durante la conferenza. Gli investitori e le parti interessate possono accedere al webcast attraverso la sezione Investitori sotto Eventi e Presentazioni su Theravance.com. La registrazione del webcast resterà disponibile sul sito web dell'azienda per 30 giorni dopo la presentazione.
Theravance Biopharma (NASDAQ: TBPH) ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La presentación de la compañía está programada para el martes 4 de marzo a las 11:50 am EST (8:50 am PST / 4:50 pm GMT).
La compañía llevará a cabo reuniones presenciales con la comunidad de inversores durante la conferencia. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores bajo Eventos y Presentaciones en Theravance.com. La grabación de la transmisión estará disponible en el sitio web de la compañía durante 30 días después de la presentación.
Theravance Biopharma (NASDAQ: TBPH)가 TD Cowen 제45회 연례 건강 관리 회의에 참가한다고 발표했습니다. 회사의 발표는 3월 4일 화요일 오전 11시 50분 EST (오전 8시 50분 PST / 오후 4시 50분 GMT)로 예정되어 있습니다.
회사는 회의 동안 투자 커뮤니티와의 대면 회의에 참여할 것입니다. 투자자 및 관심 있는 당사자는 Theravance.com의 이벤트 및 발표 섹션 아래의 투자자 섹션을 통해 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 발표 후 30일 동안 회사 웹사이트에서 이용할 수 있습니다.
Theravance Biopharma (NASDAQ: TBPH) a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. La présentation de l'entreprise est prévue pour mardi 4 mars à 11h50 EST (8h50 PST / 16h50 GMT).
L'entreprise participera à des réunions en personne avec la communauté des investisseurs pendant la conférence. Les investisseurs et les parties intéressées peuvent accéder au webinaire via la section Investisseurs sous Événements et Présentations sur Theravance.com. L'enregistrement du webinaire restera disponible sur le site de l'entreprise pendant 30 jours après la présentation.
Theravance Biopharma (NASDAQ: TBPH) hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Die Präsentation des Unternehmens ist für Dienstag, den 4. März um 11:50 Uhr EST (08:50 Uhr PST / 16:50 Uhr GMT) geplant.
Das Unternehmen wird während der Konferenz persönliche Meetings mit der Investment-Community abhalten. Investoren und interessierte Parteien können auf den Webcast über den Bereich Investoren unter Veranstaltungen und Präsentationen auf Theravance.com zugreifen. Die Aufzeichnung des Webcasts bleibt 30 Tage nach der Präsentation auf der Website des Unternehmens verfügbar.
- None.
- None.
Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302381018.html
SOURCE Theravance Biopharma, Inc.
FAQ
When is Theravance Biopharma (TBPH) presenting at the TD Cowen Healthcare Conference 2025?
How can investors access TBPH's TD Cowen conference presentation?
How long will TBPH's TD Cowen conference presentation be available for replay?
What type of investor engagement is TBPH offering at the TD Cowen conference?
